John Hoekman's most recent trade in Impel Pharmaceuticals Inc was a trade of 42,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 14, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 22 Dec 2021 | 20,000 | 128,221 | - | 1.6 | 32,800 | Common Stock |
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2021 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | 27 Apr 2021 | 69,657 | 0 | - | - | Series A-2 Preferred Stock | ||
| Impel Pharmaceuticals Inc | John Hoekman | Chief Scientific Officer | 27 Apr 2021 | 4,253 | 108,496 | - | 0 | Common Stock |